Fundamental, thesis-driven portfolio management focused on Life Sciences companies
LifeSci Fund Management
Led by the hands-on scientific and investing experience of Portfolio Manager, Mark G. Charest, Ph.D. and leverages insights across the LifeSci Partners Platform to capture capital appreciation. Subadvisor for the AlphaCentric LifeSci Healthcare Fund, a mutual fund focused on:
- Disruptive innovation in the life sciences
- Robust cash flow / revenue growth
- Direct funding through private placements, crossovers, IPOs and other structured transactions

Mark G. Charest, Ph.D.
Founding Partner and Portfolio Manager
- 12+ year career as an investor at several specialized $1B+ AUM healthcare funds
- Led Medicinal Chemistry Lab at the Novartis Institutes for BioMedical Research focused on Oncology drug discovery
- Co-inventor on 8 drug patents, including FDA-approved therapeutic
- Kauffman Fellow, National Science Foundation Graduate Research Fellow
- Ph.D. and M.S. in Chemistry and Chemical Biology from Harvard University
Senior Advisors

Michael Rice
Michael Rice
Michael Rice has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at ThinkEquity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist and Senior Managing Director at Bear Stearns.
Michael graduated from the University of Maryland with a degree in Economics and serves on the boards of Navidea (NAVD) and RDD Pharma.

Andrew McDonald
Andrew McDonald
Andrew co-founded LifeSci Partners in 2010 which has since grown to employ 100+ healthcare professionals offering a broad range of advisory services to more than 150 corporate clients in the life sciences sector.
As a scientist and former equity analyst, Andrew has a strong understanding of transformative pharmaceutical products and technologies in all stages of development, and also has a strong network across healthcare institutional investors and executives.
Prior to LifeSci, Andrew worked at Great Point Partners, a life sciences hedge fund, and headed healthcare research and was a publishing biotechnology analyst at ThinkEquity Partners. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics and at Pfizer.
Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.

Paul Yook
Paul Yook
Paul has over 20 years of healthcare investment and finance experience and in 2017 founded LifeSci Venture Partners and serves as CIO and Portfolio Manager. In 2014, Paul launched the BioShares biotechnology ETFs (NYSE: BBC & BBP) which utilize innovative and sector-specific passive index strategies and have delivered the strongest performance metrics (Sharpe ratio and total return) in their class. He previously worked at Galleon Management, as a research analyst and healthcare hedge fund portfolio manager, and in the healthcare investment banking groups of Goldman Sachs and UBS.
Paul is a passionate surfer, having lived for 3 years in Hawaii, is a mediocre but improving chess player in an effort to keep up with his two young kids, and makes an outstanding açaí bowl. He earned a B.S.E in Economics from the Wharton School and a B.A. in Biochemistry from the College of Arts and Sciences at the University of Pennsylvania.
3in3 LYFIX Episode 1
- Leveraging Pedigrees
- Fueling Innovation
- Mitigating Risk
Our Investment Approach

Perform systematic screening of life sciences corporate universe (500 + companies with > $1 Trillion aggregate market cap) using propriety fundamental scientific and financial analysis to identify watch list of potential investments

Perform sector diligence and gather Key Opinion Leader input via LifeSci network to identify highly innovative thematic areas of interest and disruptive growth opportunities; review financial metrics and ratios using proprietary analytics dashboard

Perform comprehensive fundamental analysis on prioritized companies using proprietary diligence methodology covering a broad range of factors, including scientific / medical evidence underlying key products, competitive landscape, regulatory strategy, market size, management team, and analyst coverage

Construct portfolio using thesis driven price targets for entry and exit. Relative risk / reward analysis guides position size and sub sector exposures: (1) Conduct ongoing contact with management teams and Key Opinion Leader community to validate ideas (2) Monitor price changes relative to operational progress and scientific / medical data releases
LifeSci Fund Management, LLC
-
250 West 55th Street
Suite 3401
New York, NY, 10019